LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company's segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: N/A
- Symbol: NASDAQ:LIVN
- CUSIP: N/A
- Web: www.livanova.com
- Market Cap: $3.36503 billion
- Outstanding Shares: 48,838,000
- 50 Day Moving Avg: $62.98
- 200 Day Moving Avg: $57.94
- 52 Week Range: $40.83 - $70.14
Sales & Book Value:
- Trailing P/E Ratio: 124.71
- Foreward P/E Ratio: 19.24
- P/E Growth: 1.54
- Annual Revenue: $1.21 billion
- Price / Sales: 2.82
- Book Value: $38.28 per share
- Price / Book: 1.82
- EBIDTA: $191.69 million
- Net Margins: 2.26%
- Return on Equity: 9.08%
- Return on Assets: 6.61%
- Debt-to-Equity Ratio: 0.04%
- Current Ratio: 1.96%
- Quick Ratio: 1.36%
- Average Volume: 532,862 shs.
- Beta: 0.58
- Short Ratio: 6.85
Frequently Asked Questions for LivaNova PLC (NASDAQ:LIVN)
What is LivaNova PLC's stock symbol?
LivaNova PLC trades on the NASDAQ under the ticker symbol "LIVN."
How were LivaNova PLC's earnings last quarter?
LivaNova PLC (NASDAQ:LIVN) released its quarterly earnings results on Wednesday, August, 9th. The company reported $1.01 EPS for the quarter, beating analysts' consensus estimates of $0.82 by $0.19. The business earned $321.40 million during the quarter, compared to analyst estimates of $315.75 million. LivaNova PLC had a return on equity of 9.08% and a net margin of 2.26%. LivaNova PLC's revenue was up .1% compared to the same quarter last year. View LivaNova PLC's Earnings History.
When will LivaNova PLC make its next earnings announcement?
What guidance has LivaNova PLC issued on next quarter's earnings?
LivaNova PLC issued an update on its FY17 earnings guidance on Wednesday, August, 9th. The company provided earnings per share guidance of $3.10-3.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.10.
Where is LivaNova PLC's stock going? Where will LivaNova PLC's stock price be in 2017?
7 brokerages have issued 12 month price objectives for LivaNova PLC's stock. Their predictions range from $50.00 to $83.00. On average, they expect LivaNova PLC's share price to reach $71.50 in the next twelve months. View Analyst Ratings for LivaNova PLC.
What are analysts saying about LivaNova PLC stock?
Here are some recent quotes from research analysts about LivaNova PLC stock:
- 1. Canaccord Genuity analysts commented, "We come out of LIVN’s Investor Day with a better understanding of management’s approach to turning around this business and strategic plan for augmenting long-term, organic growth; however, we do not see a high-probability pathway to material organic growth acceleration near term. Moreover, while we remain very intrigued by the firm’s big shots on goal (i.e." (9/20/2017)
- 2. Needham & Company LLC analysts commented, "LIVN announced that it is exploring strategic options for its low growth and low margin CRM business. This shouldn’t come as a huge surprise since management had previously hinted a potential sale of the CRM business. We think a CRM sale would increase LIVN’s revenue growth; the EPS impact hinges on price, CRM margins, and use of proceeds. We think a sale would be neutral to slightly dilutive if the proceeds were used for share repurchases and/or debt repayment though we note that there would likely be near-term hit to EPS between when the sale is announced and when LIVN is able to deploy the proceeds to offset any dilution." (9/14/2017)
- 3. BTIG Research analysts commented, "Last week, while we were at our Snowbird conference, LIVN reported Q4 results and released initial FY17 guidance. Once again, we are lowering our estimates for LIVN. While shares are inexpensive, we do not see how it will grow in the future unless major M&A or R&D efforts take place, moving LIVN into new markets. Given most of LIVN’s markets are flat to declining, we would be inclined to wait for the company to show intentions to enter new markets before recommending shares. We don’t expect an inflection point on cardiac surgery anytime soon and while new iterations in Neuromod may pad growth in 2H17, we think the lower end of the 1-3% revenue growth guidance would be a good achievement. There remain considerable areas of opportunity on the synergy side, which should support EPS growth. With the first innings of physical integration behind them, we think the co. is in a better position to focus on more sizeable areas of savings such as purchasing/direct procurement. However, we think the lack of revenue growth is more important than synergies and we reiterate our Neutral rating." (3/10/2017)
Who are some of LivaNova PLC's key competitors?
Some companies that are related to LivaNova PLC include DexCom (DXCM), Hill-Rom Holdings (HRC), VWR Corporation (VWR), Integra LifeSciences Holdings Corporation (IART), ICU Medical (ICUI), Neogen Corporation (NEOG), NuVasive (NUVA), Nevro Corp. (NVRO), Haemonetics Corporation (HAE), Halyard Health (HYH), Inogen (INGN), MiMedx Group (MDXG), CONMED Corporation (CNMD), OraSure Technologies (OSUR), Asante Solutions (PUMP), Cardiovascular Systems (CSII), K2M Group Holdings (KTWO) and Orthofix International N.V. (OFIX).
Who owns LivaNova PLC stock?
LivaNova PLC's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (10.42%), FMR LLC (9.84%), BlackRock Inc. (9.52%), State Street Corp (3.81%), Capital Research Global Investors (3.42%) and Koch Industries Inc. (2.92%). Company insiders that own LivaNova PLC stock include Alfred J Novak, Daniel Jeffrey Moore, Hugh M Morrison, Jacques Gutedel, Sharon O'kane and Two SCA Equinox. View Institutional Ownership Trends for LivaNova PLC.
Who sold LivaNova PLC stock? Who is selling LivaNova PLC stock?
LivaNova PLC's stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, Renaissance Technologies LLC, Employees Retirement System of Texas, OxFORD Asset Management LLP, FMR LLC, Janney Montgomery Scott LLC, JPMorgan Chase & Co. and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have sold LivaNova PLC stock in the last year include Alfred J Novak, Daniel Jeffrey Moore and Hugh M Morrison. View Insider Buying and Selling for LivaNova PLC.
Who bought LivaNova PLC stock? Who is buying LivaNova PLC stock?
LivaNova PLC's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Koch Industries Inc., State Street Corp, HealthCor Management L.P., Franklin Resources Inc., Dimensional Fund Advisors LP, Redmile Group LLC and Janus Henderson Group PLC. View Insider Buying and Selling for LivaNova PLC.
How do I buy LivaNova PLC stock?
Shares of LivaNova PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is LivaNova PLC's stock price today?
MarketBeat Community Rating for LivaNova PLC (NASDAQ LIVN)MarketBeat's community ratings are surveys of what our community members think about LivaNova PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of LivaNova PLC stock can currently be purchased for approximately $69.84.
Consensus Ratings for LivaNova PLC (NASDAQ:LIVN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.43)|
|Consensus Price Target: ||$71.50 (2.38% upside)|
Analysts' Ratings History for LivaNova PLC (NASDAQ:LIVN)
(Data available from 9/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/20/2017||Canaccord Genuity||Reiterated Rating||Hold||$71.00||Low|
|9/15/2017||Jefferies Group LLC||Boost Price Target||Buy||$76.00 -> $80.00||Low|
|9/15/2017||Needham & Company LLC||Upgrade||Hold -> Buy||$83.00||Low|
|9/12/2017||Piper Jaffray Companies||Reiterated Rating||Overweight -> Overweight||$75.00||Low|
|8/15/2017||WBB Securities||Downgrade||Hold -> Sell||$50.00||Low|
|8/11/2017||Berenberg Bank||Reiterated Rating||Buy||$70.00||Low|
|3/10/2017||BTIG Research||Reiterated Rating||Hold||N/A|
|2/29/2016||Kepler Capital Markets||Boost Price Target||Hold||$63.00 -> $66.00||N/A|
Earnings History for LivaNova PLC (NASDAQ:LIVN)Earnings History by Quarter for LivaNova PLC (NASDAQ LIVN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/1/2017|| || || || || || || || |
|8/9/2017||Q2 2017||$0.82||$1.01||$315.75 million||$321.40 million||View||Listen|
|3/1/2017||Q416||$0.79||$0.82||$301.45 million||$310.60 million||View||Listen|
|11/2/2016||Q316||$0.76||$0.78||$299.40 million||$295.30 million||View||N/A|
Earnings Estimates for LivaNova PLC (NASDAQ:LIVN)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for LivaNova PLC (NASDAQ:LIVN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for LivaNova PLC (NASDAQ:LIVN)
Insider Ownership Percentage: 0.28%Insider Trades by Quarter for LivaNova PLC (NASDAQ:LIVN)
Institutional Ownership Percentage: 82.26%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$68.55||$68,550.00|| |
|8/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$60.76||$60,760.00|| |
|7/17/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$61.55||$61,550.00|| |
|6/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$60.80||$60,800.00|| |
|5/23/2017||Sharon O'kane||Director||Buy||1,000||$58.58||$58,580.00|| |
|5/22/2017||Alfred J Novak||Director||Sell||1,000||$58.49||$58,490.00|| |
|5/5/2017||Hugh M Morrison||Director||Sell||3,215||$55.89||$179,686.35|| |
|4/17/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$51.32||$51,320.00|| |
|3/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$50.21||$50,210.00|| |
|9/22/2016||Two S.C.A. Equinox||Major Shareholder||Sell||185,000||$61.54||$11,384,900.00|| |
|9/21/2016||Two S.C.A. Equinox||Major Shareholder||Sell||391,379||$60.69||$23,752,791.51|| |
|9/16/2016||Two S.C.A. Equinox||Major Shareholder||Sell||75,213||$59.86||$4,502,250.18|| |
|9/13/2016||Two S.C.A. Equinox||Major Shareholder||Sell||25,408||$60.02||$1,524,988.16|| |
|9/8/2016||Two S.C.A. Equinox||Major Shareholder||Sell||208,000||$60.52||$12,588,160.00|| |
|8/9/2016||Jacques Gutedel||Insider||Sell||4,000||$60.52||$242,080.00|| |
|5/24/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$50.07||$50,070.00|| |
|5/19/2016||Hugh M Morrison||Director||Sell||3,600||$48.00||$172,800.00|| |
|5/6/2016||Alfred J Novak||Director||Sell||4,000||$51.12||$204,480.00|| |
|4/15/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$54.81||$54,810.00|| |
|3/15/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$56.88||$56,880.00|| |
|2/16/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$56.88||$56,880.00|| |
|1/15/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$52.64||$52,640.00|| |
|12/15/2015||Daniel Jeffrey Moore||Director||Sell||2,500||$53.97||$134,925.00|| |
Headline Trends for LivaNova PLC (NASDAQ:LIVN)
Latest Headlines for LivaNova PLC (NASDAQ:LIVN)
|LivaNova PLC (LIVN) Stock Rating Reaffirmed by Canaccord Genuity|
www.americanbankingnews.com - September 20 at 9:42 AM
|LivaNova PLC (LIVN) Director Daniel Jeffrey Moore Sells 1,000 Shares|
www.americanbankingnews.com - September 19 at 4:28 PM
|LivaNova PLC (LIVN) Receives Consensus Rating of "Hold" from Analysts|
www.americanbankingnews.com - September 17 at 9:02 AM
|LivaNova PLC (LIVN) Lifted to Buy at Needham & Company LLC|
www.americanbankingnews.com - September 16 at 8:26 PM
|LivaNova PLC (LIVN) PT Raised to $80.00|
www.americanbankingnews.com - September 15 at 2:34 PM
|LivaNova PLC (LIVN) Upgraded at Needham & Company LLC|
www.americanbankingnews.com - September 15 at 8:30 AM
|LivaNova Defines Strategic Outlook at Investor Day|
finance.yahoo.com - September 15 at 5:56 AM
|LivaNova to Explore Strategic Options for Cardiac Rhythm Management Business Franchise|
finance.yahoo.com - September 14 at 7:11 AM
|LivaNova PLC (LIVN) Now Covered by Analysts at Piper Jaffray Companies|
www.americanbankingnews.com - September 12 at 12:34 PM
|LivaNova Announces Publication of Literature Review Highlighting the Clinical Value and Safety of the Perceval Sutureless Valve for Aortic Valve Replacement|
finance.yahoo.com - September 11 at 10:33 PM
|Jefferies Group Comments on LivaNova PLC's Q3 2017 Earnings (LIVN)|
www.americanbankingnews.com - September 11 at 1:42 AM
|LivaNova PLC (LIVN) Coverage Initiated by Analysts at Jefferies Group LLC|
www.americanbankingnews.com - September 8 at 8:42 PM
|LivaNova Plc breached its 50 day moving average in a Bearish Manner : LIVN-US : August 29, 2017|
finance.yahoo.com - August 30 at 6:07 AM
|Analyzing LivaNova PLC (LIVN) and Align Technology (ALGN)|
www.americanbankingnews.com - August 24 at 10:26 PM
|LivaNova PLC (LIVN) Receives Average Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - August 23 at 9:16 AM
|Financial Review: LivaNova PLC (LIVN) & InspireMD (NSPR)|
www.americanbankingnews.com - August 20 at 2:28 PM
|LivaNova Plc breached its 50 day moving average in a Bearish Manner : LIVN-US : August 18, 2017|
finance.yahoo.com - August 18 at 8:44 PM
|Insider Selling: LivaNova PLC (LIVN) Director Sells 1,000 Shares of Stock|
www.americanbankingnews.com - August 17 at 10:24 AM
|LivaNova Plc – Value Analysis (NASDAQ:LIVN) : August 17, 2017|
finance.yahoo.com - August 17 at 1:52 AM
|LivaNova PLC (LIVN) Downgraded to "Sell" at WBB Securities|
www.americanbankingnews.com - August 15 at 11:20 AM
|LivaNova PLC (LIVN) Receives "Buy" Rating from Berenberg Bank|
www.americanbankingnews.com - August 12 at 5:42 PM
|See what the IHS Markit Score report has to say about LivaNova PLC.|
finance.yahoo.com - August 12 at 2:39 AM
|LivaNova PLC (NASDAQ:LIVN) Posts Earnings Results, Beats Expectations By $0.19 EPS|
www.americanbankingnews.com - August 11 at 11:46 PM
|LivaNova plc (LIVN) Tops Q2 EPS by 19c, Beats on Revenues; Reaffirms FY17 EPS Mid-Point Guidance Above Consensus|
www.streetinsider.com - August 10 at 2:26 AM
|LivaNova PLC beats by $0.19, beats on revenue|
seekingalpha.com - August 10 at 2:26 AM
|CORRECTING and REPLACING LivaNova Reports Second Quarter 2017 Results|
finance.yahoo.com - August 10 at 2:26 AM
|LivaNova PLC (LIVN) Updates FY17 Earnings Guidance|
www.americanbankingnews.com - August 9 at 8:46 AM
|LivaNova’s Perceval Sutureless Aortic Heart Valve Awarded New Technology Add-on Payment from the Center for Medicare and Medicaid Services|
finance.yahoo.com - August 5 at 1:30 AM
|LivaNova Plc breached its 50 day moving average in a Bearish Manner : LIVN-US : August 3, 2017|
finance.yahoo.com - August 4 at 12:14 AM
|LivaNova PLC (NASDAQ:LIVN) Set to Announce Quarterly Earnings on Wednesday|
www.americanbankingnews.com - August 2 at 7:26 AM
|VNS Therapy Receives CE Mark for Expanded MRI Labeling|
finance.yahoo.com - August 1 at 5:54 AM
|LivaNova PLC (LIVN) vs. CareFusion (CFN) Head to Head Contrast|
www.americanbankingnews.com - July 24 at 10:18 PM
|Insider Selling: LivaNova PLC (NASDAQ:LIVN) Director Sells 1,000 Shares of Stock|
www.americanbankingnews.com - July 18 at 1:44 PM
|LivaNova PLC (NASDAQ:LIVN) Short Interest Update|
www.americanbankingnews.com - July 16 at 7:23 AM
|ETFs with exposure to LivaNova Plc : July 4, 2017|
finance.yahoo.com - July 4 at 6:16 PM
|FDA Approves VNS Therapy Treatment for Drug-Resistant Epilepsy in Children as Young as Four Years Old|
finance.yahoo.com - June 30 at 1:05 AM
|LivaNova to Host Conference Call for Second Quarter 2017 Results|
finance.yahoo.com - June 27 at 6:28 PM
|LivaNova plc (LIVN) Receives FDA Approval for Expanded MRI Labeling|
www.streetinsider.com - June 21 at 4:06 PM
|VNS Therapy Receives FDA Approval for Expanded MRI Labeling|
finance.yahoo.com - June 21 at 4:06 PM
|Comparing Zimmer Biomet Holdings (ZBH) & LivaNova PLC (LIVN)|
www.americanbankingnews.com - June 18 at 6:04 PM
|ETFs with exposure to LivaNova Plc : June 16, 2017|
finance.yahoo.com - June 16 at 7:15 PM
|LivaNova Plc :LIVN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017|
finance.yahoo.com - June 14 at 10:31 AM
|LivaNova Appoints Keyna Skeffington as Senior Vice President and General Counsel|
finance.yahoo.com - June 12 at 9:40 AM
|LivaNova PLC (LIVN) and West Pharmaceutical Services (WST) Financial Comparison|
www.americanbankingnews.com - June 9 at 10:32 PM
|LivaNova PLC (LIVN) Director Sharon O'kane Purchases 1,000 Shares|
www.americanbankingnews.com - May 24 at 8:24 PM
|Alfred J. Novak Sells 1,000 Shares of LivaNova PLC (LIVN) Stock|
www.americanbankingnews.com - May 23 at 8:18 PM
|LivaNova (LIVN) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow|
seekingalpha.com - May 19 at 6:00 PM
|LivaNova PLC (LIVN) Director Hugh M. Morrison Sells 3,215 Shares|
www.americanbankingnews.com - May 9 at 4:37 PM
|LivaNova PLC to Present at the Bank of America Merrill Lynch and Jefferies Conferences|
finance.yahoo.com - May 9 at 12:00 PM
|LivaNova PLC (LIVN) Releases Earnings Results, Beats Estimates By $0.03 EPS|
www.americanbankingnews.com - May 5 at 11:53 PM
LivaNova PLC (LIVN) Chart for Sunday, September, 24, 2017